{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:30:27Z","timestamp":1793316627613,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2020,5,12]]},"abstract":"<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated several\nextra-pancreatic benefits in addition to glycemic control. This study retrospectively evaluates the realworld\nclinical effectiveness of dulaglutide as add-on therapy in overweight patients with inadequately\ncontrolled type 2 diabetes mellitus (T2DM).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>This single-center study included overweight adult patients (N, 85; women,\n45) with inadequately controlled T2DM (mean glycated hemoglobin [HbA1c] (standard deviation\n[SD]), 7.55 [0.43] %; and body mass index [BMI] [SD], 29.01 [2.30] kg\/m2) treated with dulaglutide\n(1.5 mg) once weekly as an add-on therapy. Follow-up improvements in outcomes were analyzed using\nthe paired t-test. Subgroup analysis was performed for selected outcomes. Safety parameters were\nalso evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>At the 20-week follow-up, dulaglutide based therapy demonstrated a significant reduction\n(P&lt;.001) in HbA1c, body weight and BMI, with a mean reduction (MR [SD]) of 0.45 [0.38] %, 5.06\n[2.33] kg, and 1.82 [0.81] kg\/m2, respectively, in the overall population. Similarly, reduction in urine\nalbumin\/creatinine ratio [U-ACR] (6.04 [15.53] mg\/g), cholesterol (3.24 [4.14] mg\/dL), triglycerides\n(16.60 [12.39] mg\/dL), very-low-density lipoprotein [VLDL] (3.31 [2.48] mg\/dL), serum glutamicoxaloacetic\ntransaminase (1.80 [2.92] U\/L) and glutamic-pyruvic transaminase (8.00 [5.64] U\/L) was\nalso significant (P&lt;.05). Target HbA1c of &lt;7% was achieved in 40% of patients. Reduction in HbA1c\nand body weight was significant across all subgroups analyzed. Predominantly, gastrointestinal adverse\nevents were reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Dulaglutide as an add-on therapy was well tolerated with significant improvement in\nHbA1c, body weight, BMI, U-ACR, lipid fractions and serum transaminases in overweight Indian patients\nwith T2DM.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399815666191104115449","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:13:10Z","timestamp":1572952390000},"page":"490-496","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-3321","authenticated-orcid":true,"given":"Aneesh","family":"Ghosh","sequence":"first","affiliation":[{"name":"Ananthapuri Hospitals and Research Institute, Trivandrum, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhee","family":"Nair","sequence":"additional","affiliation":[{"name":"Thiruvananthapuram Medical College, Trivandrum, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T18:37:56Z","timestamp":1592591876000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176371\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399815666191104115449","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}